‘As a producer of life-saving medication, Pharmaserve North West (PSNW) has committed to future-proofing our facilities, products, and processes. The issues and challenges posed by the investment into two prospective greener propellants have been addressed as a matter of urgency.
Through experience and great partnership, PSNW have streamlined a ‘rapid’ approach to safeguarding our existing products and future developments. Our advanced facility investment and upgrade plan, combined with our formulation screening processes, has allowed us to begin to develop the next generation of pMDIs.’
Let’s discuss how we can develop, manufacture, and commercialise your green inhaled medicine.
We develop and validate a range of analytical methods, and test for delivered dose uniformity (DDU); impurities; ethanol content; leak rate; and moisture. We conduct the full range of Product Characterisation studies required for licence submission.
We develop both Solution and Suspension formulations. Our facilities allow for both laboratory scale and pilot scale production, for volumes from 5l to 100l, and beyond to 1500l.
Our MDI manufacturing facility handles various dosage forms – Solutions, Suspensions, Inhalation, Sub-lingual – and employs Single Stage, Two Stage, and Dual Shot filling processes. The lines include check weighing and bulk packaging facilities.
Pharmaserve NW ensures an efficient solution whatever your project and requirements.
We design and manage large-scale turnkey projects, from initial formulation to final product release. This includes delivering robust processes and documentation to support any licence submission.
We assist in discrete sections of any project, whether it’s product development, analytical services, regulatory affairs, technology transfer or commercial manufacture.